Edition:
United States

BioLine RX Ltd (BLRX.OQ)

BLRX.OQ on NASDAQ Stock Exchange Capital Market

0.92USD
22 Jun 2018
Change (% chg)

$0.01 (+0.84%)
Prev Close
$0.91
Open
$0.91
Day's High
$0.96
Day's Low
$0.90
Volume
43,456
Avg. Vol
48,452
52-wk High
$1.34
52-wk Low
$0.78

Latest Key Developments (Source: Significant Developments)

Biolinerx Reports Year End 2017 Financial Results
Tuesday, 6 Mar 2018 07:00am EST 

March 6 (Reuters) - Bioline Rx Ltd ::BIOLINERX REPORTS YEAR END 2017 FINANCIAL RESULTS.BIOLINE RX LTD - COMPANY HELD $49.5 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM BANK DEPOSITS AS OF DECEMBER 31, 2017.  Full Article

BioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AML
Monday, 4 Dec 2017 07:00am EST 

Dec 4 (Reuters) - Bioline Rx Ltd ::BIOLINERX REPORTS OVERALL SURVIVAL RESULTS FROM LONG-TERM FOLLOW-UP OF PHASE 2A TRIAL IN R/R AML.BIOLINE RX-RESULTS SHOW THAT COMBINATION OF BL-8040 WITH HIGH-DOSE ARA-C SIGNIFICANTLY IMPROVED OVERALL SURVIVAL VERSUS HISTORICAL DATA OF HIDAC MONOTHERAPY.  Full Article

BioLine Rx Ltd Q3 ‍loss per ordinary share $0.07​
Tuesday, 21 Nov 2017 07:00am EST 

Nov 21 (Reuters) - BioLine Rx Ltd :BioLineRx reports third quarter 2017 financial results.BioLine Rx ltd - qtrly ‍loss per ordinary share $0.07​.  Full Article

BioLine RX says ‍​entered into at-the-market sales agreement related to offering of co's american depositary shares of up to $30 mln
Tuesday, 31 Oct 2017 05:08pm EDT 

Oct 31 (Reuters) - BioLine RX Ltd :BioLine RX Ltd - ‍​entered into at-the-market sales agreement related to offering of co's american depositary shares of up to $30 million - SEC filing.  Full Article

BioLineRX initiates phase 1b/2 trial for BL-8040 in gastric cancer under immunotherapy collaboration
Wednesday, 18 Oct 2017 07:00am EDT 

Oct 18 (Reuters) - Bioline Rx Ltd :BioLineRX announces initiation of phase 1b/2 trial for BL-8040 in gastric cancer under immunotherapy collaboration.Bioline RX Ltd - ‍Genentech commenced a phase 1b/2 study for treatment of gastric cancer with BL-8040 in combination with atezolizumab​.  Full Article

BioLineRx announces initiation of Phase 1b/2 trial for BL-8040 in AML under immunotherapy collaboration
Tuesday, 26 Sep 2017 07:00am EDT 

Sept 26 (Reuters) - Bioline Rx Ltd :BioLineRx announces initiation of Phase 1b/2 trial for BL-8040 in AML under immunotherapy collaboration.  Full Article

Biolinerx announces regulatory submission of phase 3 registrational study for BL-8040 in stem cell mobilization
Monday, 21 Aug 2017 07:00am EDT 

Aug 21 (Reuters) - Bioline Rx Ltd ::Biolinerx announces regulatory submission of phase 3 registrational study for bl-8040 in stem cell mobilization.Bioline RX Ltd - ‍initiation of study expected by end of 2017​.Bioline RX Ltd- ‍trial, named genesis, is expected to commence by end of 2017, following receipt of regulatory approval​.  Full Article

Biolinerx Q2 ‍loss per share $0.05​
Tuesday, 8 Aug 2017 07:00am EDT 

Aug 8 (Reuters) - Bioline Rx Ltd ::Biolinerx reports second quarter 2017 financial results.Qtrly ‍loss per share $0.05​.  Full Article

Biolinerx announces additional investment from BVF Partners L.P.
Wednesday, 26 Jul 2017 07:00am EDT 

July 26 (Reuters) - BiolineRx Ltd :BiolineRx announces additional investment from BVF partners L.P..BiolineRx Ltd - BVF partners L.P enters into a definitive agreement to make an additional, direct investment of $9.6 million in biolinerx.BiolineRX Ltd - bvf's new investment is priced at $1.13 per unit.BiolineRX Ltd - each unit consists of 1 ordinary share, 0.35 of a series A warrant, and 0.35 of a series B warrant.BiolineRX Ltd - BVF Partners L.P raises its economic interest in BiolineRX to 24.9 percent.  Full Article

BiolineRx reports regulatory submissions of 3 Phase 1b trials for BL-8040 in combination with atezolizumab for solid tumors
Thursday, 1 Jun 2017 07:00am EDT 

June 1 (Reuters) - Bioline Rx Ltd ::BiolineRx reports regulatory submissions of three phase 1b trials for BL-8040 in combination with atezolizumab for solid tumors.Bioline Rx - trials for pancreatic, gastric and non-small cell cancer expected to commence during second half of 2017, after receipt of regulatory approval.  Full Article

BRIEF-BioLineRx Reports Qtrly Loss Per Share $0.06

* QTRLY LOSS PER ORDINARY SHARE BASIC AND DILUTED $0.06 Source text for Eikon: Further company coverage:

No consensus analysis data available.